Clin2
NCT04300556Possibly a fitRecruiting

Testing an antibody-drug for advanced certain cancers

Solid Tumor

Treatments studied

Part of Cancer, Hormones & metabolism, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.

This early-phase trial tests a treatment called MORAb-202, an antibody “delivery” drug, to see if it’s safe and can help shrink or control certain advanced cancers. It may help people whose tumors match the study’s specific cancer types and prior treatment history.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
182 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You’re 18 years or older.
  • You have one of these advanced cancers: TNBC breast cancer, lung adenocarcinoma (NSCLC), endometrial cancer, or high-grade serous ovarian/fallopian tube/primary peritoneal cancer.
  • Your cancer has gotten worse after prior treatment, and you’ve had limited lines of systemic cancer therapy (not many different treatments).
  • Your tumor tissue sample can be tested for “FR-alpha” using a lab test (IHC); the sample must be usable for testing.
  • Your overall health labs are acceptable: heart/liver/kidney function and bone marrow counts meet trial thresholds.
  • You must be able to come off prior cancer medicines for the required washout time before starting this study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05159245Recruiting· Phase 2
Targeted drug access for adults with advanced cancer

This trial helps match people with advanced, hard-to-treat cancers to targeted cancer drugs based on lab testing of their tumor. It may help if standard treatment isn’t working or isn’t available, and if your tumor has a “targetable” genetic change.

Turku, Southwest Finland
NCT05490472Recruiting· Phase 1/Phase 2
Study drug for advanced solid tumors that stopped responding

This early study tests a new medicine (JAB-2485) in adults with advanced solid tumors (cancers that have spread or grown locally). You may join to see if it can shrink tumors or control the disease when other treatments haven’t worked or weren’t tolerated.

Detroit, Michigan
NCT06233942Recruiting· Phase 1
Testing a new drug for advanced solid tumors

This early-phase trial tests a new drug called BG-C9074, either alone or with other cancer treatments, for people with certain advanced solid tumors that have not responded to standard therapy. The goal is to see if it is safe and effective.

Los Angeles, California
NCT06226363Not yet recruiting· Phase 1
New drug LNF1901 for advanced solid tumors

This trial tests a new experimental drug called LNF1901 for people with advanced cancers that have not responded to or cannot tolerate standard treatments. It aims to see if the drug is safe and effective.

NCT05471856Recruiting· Phase 1
Test different doses of cancer drugs with ezabenlimab

This Phase 1 trial tests how different doses of a study drug (BI 1703880) work and how safe they are when given with ezabenlimab for advanced solid tumors. It’s for people whose cancer can’t be removed with surgery and who have tried standard treatments or can’t get them.

Los Angeles, California
NCT06825494Recruiting· Phase 1/Phase 2
Study of a new drug for advanced solid tumors

This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.

Hefei, Anhui

Hear when a new Solid Tumor trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.